| __timestamp | Amicus Therapeutics, Inc. | TG Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 24518692 |
| Thursday, January 1, 2015 | 47269000 | 19886580 |
| Friday, January 1, 2016 | 71151000 | 12631689 |
| Sunday, January 1, 2017 | 88671000 | 21977998 |
| Monday, January 1, 2018 | 127200000 | 20759000 |
| Tuesday, January 1, 2019 | 169861000 | 20838000 |
| Wednesday, January 1, 2020 | 156407000 | 121812000 |
| Friday, January 1, 2021 | 192710000 | 152137000 |
| Saturday, January 1, 2022 | 213041000 | 83231000 |
| Sunday, January 1, 2023 | 275270000 | 122706000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, effective cost management is crucial. Over the past decade, Amicus Therapeutics, Inc. and TG Therapeutics, Inc. have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses.
From 2014 to 2023, Amicus Therapeutics saw a staggering 1,230% increase in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, TG Therapeutics experienced a more modest 400% rise, with a significant spike in 2020, indicating a strategic pivot or expansion during that period.
These trends highlight the dynamic nature of the biotech sector, where companies must balance growth ambitions with financial prudence. As investors and stakeholders analyze these patterns, understanding the nuances of SG&A management becomes essential for predicting future performance and sustainability.
Comparing SG&A Expenses: BeiGene, Ltd. vs Amicus Therapeutics, Inc. Trends and Insights
Selling, General, and Administrative Costs: Exelixis, Inc. vs Amicus Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs TG Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alkermes plc and Amicus Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing TG Therapeutics, Inc. and PTC Therapeutics, Inc.
Breaking Down SG&A Expenses: TG Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: TG Therapeutics, Inc. vs ImmunityBio, Inc. Trends and Insights
Amicus Therapeutics, Inc. or Vericel Corporation: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and HUTCHMED (China) Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Amicus Therapeutics, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Amicus Therapeutics, Inc. vs Mesoblast Limited
Selling, General, and Administrative Costs: Amicus Therapeutics, Inc. vs Travere Therapeutics, Inc.